Guillain-Barre syndrome after vaccination in United States a report from the CDC/FDA Vaccine Adverse Event Reporting System

Nizar Souayah; Abu Nasar; M Fareed K Suri; Adnan I Qureshi

doi:10.1016/j.vaccine.2007.03.053

Guillain-Barre syndrome after vaccination in United States a report from the CDC/FDA Vaccine Adverse Event Reporting System

Vaccine. 2007 Jul 20;25(29):5253-5. doi: 10.1016/j.vaccine.2007.03.053. Epub 2007 May 22.

Authors

Nizar Souayah¹, Abu Nasar, M Fareed K Suri, Adnan I Qureshi

Affiliation

¹ Epidemiological and Outcomes Research Division, Zeenat Qureshi Stroke Research Center, Department of Medicine, University of Medicine and Dentistry of New Jersey, 90 Bergen Street, DOC 8100, Newark, NJ 07103, United States. souayani@umdny.edu

PMID: 17560693
DOI: 10.1016/j.vaccine.2007.03.053

Abstract

Using the data from Vaccine Adverse Event Reporting System, we present 54 reports of Guillain-Barre Syndrome (GBS) after vaccination that occurred in United States in 2004. In 38 of the patients, GBS occurred within 6 weeks. The highest number (n=31) of GBS was observed in patients receiving influenza vaccine followed by hepatitis vaccine (n=9), 1 patient died and 10 patients were disabled following the event. We conclude that vaccines other than influenza vaccine can be associated with GBS.

MeSH terms

Adult
Adverse Drug Reaction Reporting Systems
Guillain-Barre Syndrome / epidemiology*
Humans
Incidence*
Influenza Vaccines / adverse effects
United States
Vaccination / adverse effects*

Substances

Influenza Vaccines